Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
A Phase 1 Multi-center clinical Trial Evaluating the Safety and Tolerability of
5-aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic
Therapy (SDT) in Patients With recurrent High Grade Glioma (HGG)